axicabtagene ciloleucel (Yescarta) Report issue

Cell therapy Orphan Drug FDA Approved FDA Breakthrough Therapy FDA
AACT

Active Ingredient History

NOW
  • Now
Axicabtagene ciloleucel, sold under the brand name Yescarta, is a medication used for the treatment for large B-cell lymphoma that has failed conventional treatment. T cells are removed from a person with lymphoma and genetically engineered to produce a specific T-cell receptor. The resulting chimeric antigen receptor T cells (CAR-Ts) that react to the cancer are then given back to the person to populate the bone marrow. Axicabtagene treatment carries a risk for cytokine release syndrome (CRS) and neurological toxicities.   Wikipedia

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Missing data
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: Missing data

Drug Pricing (per unit)

United States

$284904.5200 - $373000.0000
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

axicabtagene ciloleucel | kte-c19

Organizations (22)

Research & Development (22)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (15)

Approved Indications (3)


 

Lymphoma, B-Cell (approved 2017)

Lymphoma, Follicular (approved 2021)

Lymphoma, Large B-Cell, Diffuse (approved 2017)

Experimental Indications - Clinical Trial Phases 1-4 (15)


 

Cytokine Release Syndrome (Phase 2)

Drug-Related Side Effects and Adverse Reactions (Phase 2)

HIV Infections (Phase 1)

Hodgkin Disease (Phase 2)

Lymphoma (Phase 1/Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Follicular (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Neoplasms (Phase 2)

Neurotoxicity Syndromes (Phase 2)

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 31
  • # of Trial Organizations: 22

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue